References
  1. Charles J. Parker. The pathophysiology of paroxysmal nocturnal hemoglobinuria. Exp Hematol. 2007,5:523-533.
  2. Kinoshita T. Molecular genetics, biochemistry, and biology of PNH. Rinsho Ketsueki. 2017;58(4):353-362.
  3. Brodsky RA, Young NS, Antonioli E, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria[J]. Blood, 2008,111(4):1840-1847.
  4. .Sicre de Fontbrune F, Peffault de Latour R. Ten years of clinical experience with eculizumab in patients with paroxysmal nocturnal hemoglobinuria[J]. Semin Hematol,2018,55(3):124-129.
  5. Patriquin CJ, Kiss T, Caplan S, et al. How we treat paroxysmal nocturnal hemoglobinuria: A consensus statement of the Canadian PNH Network and review of the national registry[J]. Eur J Haematol, 2019,102(1):36-52.
  6. Kulasekararaj AG, Hill A, Rottinghaus ST, et al. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study[J]. Blood, 2019,133(6):540-549.
  7. Röth A, Nishimura JI, Nagy Z, et al. The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria[J]. Blood, 2020, 135 (12): 912-920.
  8. Schols S, Nunn MA, Mackie I, et al. Successful treatment of a PNH patient non-responsive to eculizumab with the novel complement C5 inhibitor coversin (nomacopan)[J]. Br J Haematol, 2020, 188(2):334-337.
  9. .Schatz-Jakobsen JA, Zhang Y, Johnson K, et al. Structural Basis for Eculizumab-Mediated Inhibition of the Complement Terminal Pathway. J Immunol. 2016,97(1):337-44.
  10. Alfinito F, Ruggiero G, Sica M, et al. Eculizumab treatment modified the immune profile of PNH patients. Immunobiology. 2012,217(7):698-703.
  11. Cooper JP, Farah RJ, Stevenson PA, Gooley TA, Storb R, Scott BL. Biol Hematopoietic Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria in the Age of Eculizumab.Blood Marrow Transplant. 2019 Jul;25(7):1331-1339.
  12. .Lee SE,Park SS, Jeon YW, et al. Outcomes of allogeneic stem cell transplantation in patients with paroxysmal nocturnal hemoglobinuria with or without aplastic anemia. Eur J Haematol. 2017 Jul 4.
  13. Tian H, Liu L, Chen J, Xu Y, Jin Z, Miao M, Fu Z, Qiu H, Sun A, Wu D. Haploidentical hematopoietic stem cell transplant in paroxysmal nocturnal hemoglobinuria. Leuk Lymphoma. 2016;57(4):835-41.
  14. Chen F, Wu D, Tang X, et al. Outcomes of allogeneic hematopoietic stem cell transplantation for 18 patients with paroxysmal nocturnal haemoglobinuria. Zhonghua Xue Ye Xue Za Zhi. 2015 Dec;36(12):1005-10.
  15. Chinese Society of Hematology, Chinese Medical Association. Expert consensus of diagnosis and treatment of paroxysmal nocturnal hemoglobinuria. Zhonghua Xue Ye Xue Za Zhi 34:276-279, 2013.
  16. Ge ML, Li XX, Shao YQ, Shi J, Zheng YZ. Clinical Analysis of 70 Adult Patients with Paroxysmal Nocturnal Hemoglobinuria. Journal of Experimental Hematology. 2015, 23(3): 774~778.
  17. Fu R, Li L, Li L, Liu H, Zhang T, Ding S, Wang G, Song J, Wang H, Xing L, Guan J, Shao Z. Analysis of clinical characteristics of 92 patients with paroxysmal nocturnal hemoglobinuria: A single institution experience in China. J Clin Lab Anal. 2020 Jan;34(1):e23008.
  18. .Hill A, DeZern AE, Kinoshita T, Brodsky RA. Paroxysmal nocturnal haemoglobinuriaNat Rev Dis Primers. 2017 May 18;3:17028.
  19. N E Hansen, S A Killmann. Paroxysmal nocturnal haemoglobinuria. A clinical study. Acta Med Scand1968 Dec;184(6):525-41.
  20. N E Hansen, S A Killmann. Paroxysmal nocturnal haemoglobinuria. A clinical study. Acta Med Scand1968 Dec;184(6):525-41.
  21. Xi-feng Dong, Rong Fu, Hua-quan Wang, Zong-hong Shao. Chemotherapy plus hematopoietic growth factors for refractory paroxysmal nocturnal hemoglobinuria: diminishing PNH clone and stimulating hematopoisis. Journal of Society for development in new net environment in B&H,2012:6,2749-2756.
  22. Cao YR, Shao ZH, Jia HR, Sun J, Liu H, Wu YH, Qin TJ, Shi J, Bai J, He GS, Fu R, Zhao MF, Tu HF, Cui ZZ, Yang TY. Preliminary study of DA or HA regimen chemotherapy for the treatment of refractory and relapsed paroxysmal nocturnal hemoglobinuria. Zhonghua Xue Ye Xue Za Zhi. 2004 Apr;25(4):202-4.
  23. Shao ZH, Zhao MF, Li K, Liu H, Yang TY, Shi J, He GS, He H, Zhang H,Chen GB, Chu YL,Yang TY. Efficacy of low-dose combined chemotherapy on refractory and recurrent paroxysmal nocturnal hemoglobinuria Chinese Journal of Practical Internal Medicine,2000,20:10,607-609.
  24. Stern RM, Connell NT. Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria[J]. Ther Adv Hematol, 2019, 10: 20406207 19874728.
  25. Kulasekararaj AG, Hill A, Rottinghaus ST, et al. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study[J]. Blood, 2019,133(6):540-549.
  26. Lee JW, Sicre de Fontbrune F, Wong Lee Lee L, et al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study[J]. Blood, 2019, 133(6): 530-539.
  27. Risitano AM, Marotta S, Ricci P, et al. Anti-complement treatment for paroxysmal nocturnal hemoglobinuria: time for proximal complement inhibition? A position paper from the SAAWP of the EBMT[J]. Front Immunol, 2019, 10: 1157.